Lv7
5000 积分 2023-02-15 加入
Phase 1 study of GCC2005, an allogeneic CD5‑directed CAR‑NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies
2个月前
已完结
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma
2个月前
已完结
Toripalimab monotherapy for newly diagnosed early‑stage extranodal NK/T-cell lymphoma: a phase 2 trial
2个月前
已关闭
Cord blood-derived CD30‑CAR‑NK cells plus AFM13 for relapsed/refractory CD30+ lymphomas (including ENKTL)
2个月前
已关闭
Phase 1 study of GCC2005, an allogeneic CD5‑directed CAR‑NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies
2个月前
已完结
CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
2个月前
已完结
Anti‑CD30 chimeric antigen receptor T‑cell therapy for relapsed/refractory CD30+ lymphoma: a phase 1 trial
2个月前
已关闭
CD7‑targeted CAR‑T cell therapy for relapsed/refractory extranodal NK/T-cell lymphoma: a phase 1/2 trial
2个月前
已关闭
Brentuximab Vedotin Plus Sintilimab for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: A Phase 2 Trial
2个月前
已关闭
Brentuximab vedotin for relapsed/refractory extranodal NK/T-cell lymphoma: A multicenter phase 2 trial
2个月前
已完结
皖公网安备34019202002308
